AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 ...

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an "unfair" assessment process for NHS drug approval. At such a critical moment in ...

Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.

This improved accuracy when deciding which patients with HER2-low and HER2-ultralow status should be treated with the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu; Daiichi Sankyo ...

A WIRRAL woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as her having "lumpy boobs" for ...

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs ...